TMCnet News
Global Postherpetic Neuralgia Pipeline Review, H2 2016 - Research and MarketsResearch and Markets has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2016" report to their offering. Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively. Postherpetic Neuralgia Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin's lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers. Postherpetic Neuralgia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route f administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/6khjcd/postherpetic
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005362/en/ |